Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
248
datasets available to search
ShareScore release 0.9.0
Dataset results
248 results for “OCD”
Supplementary material: Negative valence in Obsessive-Compulsive Disorder: A worldwide mega-analysis of task-based functional neuroimaging data of the ENIGMA-OCD consortium
<p>The ridge plots attached here accompany the supplement to the manuscript <em>Negative valence in Obsessive-Compulsive Disorder: A worldwide mega-analysis of task-based functional neuroimaging data of the ENIGMA-OCD consortium</em> (Dzinalija et al., 2024)<em>. </em>These are full results of Figures 1, 2C, and 3C of the manuscript and Figures S3, S5, S7 and S9 of the supplement depicting whole-brain Bayesian multilevel models run using the Regional Bayesian Analysis toolbox (RBA; Chen et al., 2019). Whole-brain analyses were parcelated into the Schaefer-Yeo 7-network 200-parcel cortical atlas (Schaefer et al., 2018) and the Melbourne 32-region subcortical atlas (Tian et al., 2020). Results are presented according to contrast of interests: [Negative > Neutral], [OCD > Neutral], [Threat > Neutral], and [OCD > Threat], and effects of interest: [Diagnosis = OCD or HC], [MED = medication], [AO = age of onset], [YBOCS = OCD severity], and [Intercept = task effect]. </p> <p>P+ values denote the probability that there is increased brain activation in a given region of the Schaefer 200-parcel 7-network cortical atlas and Melbourne 32-region subcortical atlas. We used the guidelines proposed by Chen et al. (2019) to infer credibility of evidence, namely taking a positive posterior probability (P+) of <0.10 or >0.90 as indication of moderate evidence and, <0.05 or >0.95 or <0.025 or >0.975 as strong or very strong evidence, respectively. To interpret the pairwise comparisons presented as Group1-vs-Group2, posterior distributions to the right of the green no-effect line represent regions in which individuals in Group 1 show credible evidence for higher activation than individuals in Group 2. Regions with posterior distributions to the left of this line show credible evidence for higher activity in Group 2 than in Group 1. (Darker) red color represents regions in which individuals in Group 1 show moderate-to-very-strong evidence for higher activation than Group 2. (Darker) blue color represents regions in which Group 2 show moderate-to-very-strong evidence for higher activation than Group 1. Grey color represents regions in which there is no strong evidence of a difference between Group 1 and Group 2. Schaefer-Yeo 200-parcel atlas name abbreviations can be retrieved <a href="https://github.com/ThomasYeoLab/CBIG/tree/master/stable_projects/brain_parcellation/Schaefer2018_LocalGlobal/Parcellations">via this link.</a></p>
Overlapping Neural Circuits in Pediatric OCD
ClinicalTrials.gov study NCT02421315. IPD Sharing: YES. Countries: 1. Publications: 4.
Duloxetine for the Treatment of Obsessive Compulsive Disorder (OCD)
ClinicalTrials.gov study NCT00464698. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Dealing With Intrusive Thoughts in OCD - a Comparison of Detached Mindfulness and Cognitive Restructuring
ClinicalTrials.gov study NCT03002753. IPD Sharing: Not stated. Countries: 1. Publications: 10.
Pilot Study of Minocycline (NPL-2003) in Adults With Obsessive-Compulsive Disorder (OCD)
ClinicalTrials.gov study NCT00728923. IPD Sharing: Not stated. Countries: 1. Publications: 1.
2/2 D-Cycloserine Augmentation of CBT for Pediatric OCD
ClinicalTrials.gov study NCT01404208. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Transcranial Magnetic Stimulation (TMS) in Obsessive Compulsive Disorder (OCD): Mechanisms and Biomarkers
ClinicalTrials.gov study NCT02355002. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Digital Health Interventions for Obsessive Compulsive Disorder (OCD)
ClinicalTrials.gov study NCT04136626. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Study to Evaluate the Effect of AFQ056 in Obsessive Compulsive Disorder (OCD) Patients Resistant to Selective Serotonin Reuptake Inhibitor (SSRI) Therapy
ClinicalTrials.gov study NCT01813019. IPD Sharing: Not stated. Countries: 5. Publications: 1.
Rapid Non-Invasive Brain Stimulation for OCD (oTMS)
ClinicalTrials.gov study NCT03404609. IPD Sharing: Not stated. Countries: 1. Publications: 1.
SPACE: a Parent-based Treatment for Pediatric OCD
ClinicalTrials.gov study NCT06356090. IPD Sharing: YES. Countries: 1. Publications: 1.
Dextro-Amphetamine Versus Caffeine in Treatment-resistant OCD
ClinicalTrials.gov study NCT00363298. IPD Sharing: NO. Countries: 1. Publications: 1.
HANDS-ON: a Personalized, Brief and Intensive Exposure-based Intervention for Youth With Persistent Anxiety or OCD
ClinicalTrials.gov study NCT06152913. IPD Sharing: YES. Countries: 1. Publications: 3.
Effects of Sertraline on Brain Connectivity in Adolescents With OCD
ClinicalTrials.gov study NCT02797808. IPD Sharing: NO. Countries: 1. Publications: 2.
TMS + Exposure Therapy for Pediatric OCD
ClinicalTrials.gov study NCT05931913. IPD Sharing: YES. Countries: 1. Publications: 1.
Transcranial Magnetic Stimulation (TMS) and Obsessive Compulsive Disorder (OCD)
ClinicalTrials.gov study NCT00106249. IPD Sharing: NO. Countries: 1. Publications: 6.
D-cycloserine Augmentation of Cognitive Behavioral Therapy (CBT) for Pediatric Obsessive-compulsive Disorder (OCD)
ClinicalTrials.gov study NCT01411774. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Pilot Study of Ketamine in Adults With Obsessive-Compulsive Disorder (OCD)
ClinicalTrials.gov study NCT01100255. IPD Sharing: NO. Countries: 1. Publications: 3.
Exploring The Metacognitive Beliefs in OCD: A Randomized Controlled Trial of Metacognitive Therapy
ClinicalTrials.gov study NCT07052812. IPD Sharing: NO. Countries: 1. Publications: 2.
Ketamine Treatment for Pediatric-Refractory Obsessive-Compulsive Disorder (OCD)
ClinicalTrials.gov study NCT02422290. IPD Sharing: NO. Countries: 1. Publications: 23.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.